Cytokines in sepsis: Potent immunoregulators and potential therapeutic targets - An updated view

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Schulte, Wibke ^a,b   Bernhagen, Jürgen ^b   Bucala, Richard ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; CYTOKINE; DROTRECOGIN; GAMMA INTERFERON; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PLACEBO; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; IMMUNOLOGIC FACTOR;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CAUSE OF DEATH; CYTOKINE RELEASE; DEFENSE MECHANISM; DISEASE SEVERITY; DRUG TREATMENT FAILURE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFECTION RATE; INFLAMMATION; INNATE IMMUNITY; INTENSIVE CARE UNIT; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SURVIVAL; TISSUE INJURY; ANIMAL; DISEASE COURSE; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; PATHOLOGY; REVIEW; TREATMENT OUTCOME;

ANIMALS; CYTOKINES; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; SEPSIS; TREATMENT OUTCOME;

EID: 84880171917     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/165974     Document Type: Article

References (230)

1. Bone R. C., Balk R. A., Cerra F. B., Dellinger R. P., Fein A. M., Knaus W. A., Schein R. M., Sibbald W. J., Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992 101 6 1644 1655 2-s2.0-77649201783
2. Angus D. C., Linde-Zwirble W. T., Lidicker J., Clermont G., Carcillo J., Pinsky M. R., Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical Care Medicine 2001 29 7 1303 1310 2-s2.0-0034958947 (Pubitemid 32641789)
3. Martin G. S., Mannino D. M., Eaton S., Moss M., The epidemiology of sepsis in the United States from 1979 through 2000. The New England Journal of Medicine 2003 348 16 1546 1554 2-s2.0-0037451929 10.1056/NEJMoa022139 (Pubitemid 36437931)
4. Dombrovskiy V. Y., Martin A. A., Sunderram J., Paz H. L., Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Critical Care Medicine 2007 35 5 1244 1250 2-s2.0-34247338128 10.1097/01.CCM.0000261890.41311.E9 (Pubitemid 46642649)
5. Anel R., Kumar A., Human endotoxemia and human sepsis: limits to the model. Critical Care 2005 9 2 151 152 2-s2.0-15844365645 10.1186/cc3501 (Pubitemid 40425438)
6. van der Poll T., Opal S. M., Host-pathogen interactions in sepsis. The Lancet Infectious Diseases 2008 8 1 32 43 2-s2.0-39149097579 10.1016/S1473-3099(07)70265-7
7. Chalupka A. N., Talmor D., The economics of sepsis. Critical Care Clinics 2012 28 1 57 76 2-s2.0-82955177065 10.1016/j.ccc.2011.09.003
8. Burchardi H., Schneider H., Economic aspects of severe sepsis: a review of intensive care unit costs, cost of illness and cost effectiveness of therapy. PharmacoEconomics 2004 22 12 793 813 2-s2.0-4344604019 10.2165/00019053- 200422120-00003 (Pubitemid 39158998)
9. Geroulanos S., Douka E. T., Historical perspective of the word 'sepsis'. Intensive Care Medicine 2006 32 12 2077 2-s2.0-33751552449 10.1007/s00134-006- 0392-2 (Pubitemid 44833126)
10. Dellinger R. P., Levy M. M., Rhodes A., Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Critical Care Medicine 2013 41 2 580 637
11. Levy M. M., Fink M. P., Marshall J. C., Abraham E., Angus D., Cook D., Cohen J., Opal S. M., Vincent J., Ramsay G., 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Critical Care Medicine 2003 31 4 1250 1256 2-s2.0-0037389094 10.1097/01.CCM.0000050454.01978.3B (Pubitemid 36444440)
12. Alberti C., Brun-Buisson C., Goodman S. V., Guidici D., Granton J., Moreno R., Smithies M., Thomas O., Artigas A., Le Gall J. R., Influence of systemic inflammatory response syndrome and sepsis on outcome of critically III infected patients. American Journal of Respiratory and Critical Care Medicine 2003 168 1 77 84 2-s2.0-0042805302 10.1164/rccm.200208-785OC (Pubitemid 37046636)
13. Alberti C., Brun-Buisson C., Chevret S., Antonelli M., Goodman S. V., Martin C., Moreno R., Ochagavia A. R., Palazzo M., Werdan K., Le Gall J. R., Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. American Journal of Respiratory and Critical Care Medicine 2005 171 5 461 468 2-s2.0-20144387559 10.1164/rccm.200403-324OC (Pubitemid 40444246)
14. Pittet D., Rangel-Frausto S., Li N., Tarara D., Costigan M., Rempe L., Jebson P., Wenzel R. P., Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Medicine 1995 21 4 302 309 2-s2.0-0029024552 10.1007/BF01705408
15. Dellinger R. P., Carlet J. M., Masur H., Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Critical Care Medicine 2004 32 3 858 873 (Pubitemid 38344143)
16. Cohen J., The immunopathogenesis of sepsis. Nature 2002 420 6917 885 891 2-s2.0-0037180768 10.1038/nature01326 (Pubitemid 36019643)
17. Hansen J. D., Vojtech L. N., Laing K. J., Sensing disease and danger: a survey of vertebrate PRRs and their origins. Developmental and Comparative Immunology 2011 35 9 886 897 2-s2.0-79958205445 10.1016/j.dci.2011.01.008
18. Rivers E., Nguyen B., Havstad S., Ressler J., Muzzin A., Knoblich B., Peterson E., Tomlanovich M., Early goal-directed therapy in the treatment of severe sepsis and septic shock. The New England Journal of Medicine 2001 345 19 1368 1377 2-s2.0-0035829842 10.1056/NEJMoa010307
19. Denk S., Perl M., Huber-Lang M., Damage- and pathogen-associated molecular patterns and alarmins: keys to sepsis? European Surgical Research 2012 48 4 171 179
20. Levi M., van der Poll T., Inflammation and coagulation. Critical Care Medicine 2010 38 supplement 2 S26 S34 2-s2.0-74949117097 10.1097/CCM. 0b013e3181c98d21
21. Atsumi T., Cho Y., Leng L., McDonald C., Yu T., Danton C., Hong E., Mitchell R. A., Metz C., Niwa H., Takeuchi J., Onodera S., Umino T., Yoshioka N., Koike T., Kim J. K., Bucala R., The proinflammatory cytokine macrophage migration inhibitory factor regulates glucose metabolism during systemic inflammation. The Journal of Immunology 2007 179 8 5399 5406 2-s2.0-38449097890
22. Mlinar B., Marc J., New insights into adipose tissue dysfunction in insulin resistance. Clinical Chemistry and Laboratory Medicine 2011 49 12 1925 1935 2-s2.0-84856274444 10.1515/CCLM.2011.697
23. Emonts M., Sweep F. C. G. J., Grebenchtchikov N., Geurts-Moespot A., Knaup M., Chanson A. L., Erard V., Renner P., Hermans P. W. M., Hazelzet J. A., Calandra T., Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clinical Infectious Diseases 2007 44 10 1321 1328 2-s2.0-34248195568 10.1086/514344 (Pubitemid 46717294)
24. Capuron L., Miller A. H., Immune system to brain signaling: neuropsychopharmacological implications. Pharmacology and Therapeutics 2011 130 2 226 238 2-s2.0-79953662385 10.1016/j.pharmthera.2011.01.014
25. Hook K. M., Abrams C. S., The loss of homeostasis in hemostasis: new approaches in treating and understanding acute disseminated intravascular coagulation in critically ill patients. Clinical and Translational Science 2012 5 1 85 92 2-s2.0-84857644310 10.1111/j.1752-8062.2011.00351.x
26. Hotchkiss R. S., Nicholson D. W., Apoptosis and caspases regulate death and inflammation in sepsis. Nature Reviews Immunology 2006 6 11 813 822 2-s2.0-33750288937 10.1038/nri1943 (Pubitemid 44631650)
27. Volk H., Reinke P., Döcke W., Clinical aspects: from systemic inflammation to 'immunoparalysis'. Chemical Immunology 2000 74 162 177 2-s2.0-0032734726
28. Germain R. N., Maintaining system homeostasis: the third law of Newtonian immunology. Nature Immunology 2012 13 10 902 906
29. Hotchkiss R. S., Opal S., Immunotherapy for sepsis-a new approach against an ancient foe. The New England Journal of Medicine 2010 363 1 87 89 2-s2.0-77954183132 10.1056/NEJMcibr1004371
30. Akira S., Uematsu S., Takeuchi O., Pathogen recognition and innate immunity. Cell 2006 124 4 783 801 2-s2.0-32944464648 10.1016/j.cell.2006.02.015 (Pubitemid 43261452)
31. Ishii K. J., Koyama S., Nakagawa A., Coban C., Akira S., Host innate immune receptors and beyond: making sense of microbial infections. Cell Host and Microbe 2008 3 6 352 363 2-s2.0-44649132540 10.1016/j.chom.2008.05.003 (Pubitemid 351773099)
32. Akira S., Takeda K., Toll-like receptor signalling. Nature Reviews Immunology 2004 4 7 499 511 2-s2.0-3142724031 (Pubitemid 38931765)
33. Lakhani S. A., Bogue C. W., Toll-like receptor signaling in sepsis. Current Opinion in Pediatrics 2003 15 3 278 282 2-s2.0-0037952671 10.1097/00008480-200306000-00009 (Pubitemid 36578077)
34. O'Neill L. A. J., A critical role for citrate metabolism in LPS signalling. Biochemical Journal 2011 438 3 e5 e6 2-s2.0-80052155391 10.1042/BJ20111386
35. Jawien J., New insights into immunological aspects of atherosclerosis. Polskie Archiwum Medycyny Wewnetrznej 2008 118 3 127 131 (Pubitemid 351488259)
36. Choy E., Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology 2012 51 supplement 5 v3 v11
37. Parameswaran N., Patial S., Tumor necrosis factor-a signaling in macrophages. Critical Reviews in Eukaryotic Gene Expression 2010 20 2 87 103 2-s2.0-79651471957
38. Rubio-Perez J. M., Morillas-Ruiz J. M., A review: inflammatory process in Alzheimer's disease, role of cytokines. The Scientific World Journal 2012 2012 15 756357 10.1100/2012/756357
39. Dinarello C. A., Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. Journal of Endotoxin Research 2004 10 4 201 222 2-s2.0-8344261590 10.1179/096805104225006129 (Pubitemid 39481010)
40. Feldmann M., Brennan F. M., Elliott M., Katsikis P., Maini R. N., TNF as a therapeutic target in rheumatoid arthritis. Circulatory Shock 1994 43 4 179 184 2-s2.0-0028658445
41. Modzelewski B., The role of soluble TNF p55 and p75 receptors in the development of septic syndrome. Polski Merkuriusz Lekarski 2003 14 79 69 72 2-s2.0-0037215083 (Pubitemid 36292533)
42. Schouten M., Wiersinga W. J., Levi M., van der Poll T., Inflammation, endothelium, and coagulation in sepsis. Journal of Leukocyte Biology 2008 83 3 536 545 2-s2.0-43349096795 10.1189/jlb.0607373 (Pubitemid 351966862)
43. Witsell A. L., Schook L. B., Tumor necrosis factor alpha is an autocrine growth regulator during macrophage differentiation. Proceedings of the National Academy of Sciences of the United States of America 1992 89 10 4754 4758
44. Dinarello C. A., Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 1997 112 supplement 6 321S 329S 2-s2.0-0031452476 (Pubitemid 28013408)
45. Fisher C. J. Jr., Agosti J. M., Opal S. M., Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. The New England Journal of Medicine 1996 334 26 1697 1702 (Pubitemid 26193621)
46. Fong Y., Tracey K. J., Moldawer L. L., Hesse D. G., Manogue K. B., Kenney J. S., Lee A. T., Kuo G. C., Allison A. C., Lowry S. F., Cerami A., Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 β and interleukin 6 appearance during lethal bacteremia. Journal of Experimental Medicine 1989 170 5 1627 1633 2-s2.0-0024822793 (Pubitemid 19284562)
47. O'Neill L. A. J., The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunological Reviews 2008 226 1 10 18 2-s2.0-55149105005 10.1111/j.1600-065X.2008.00701.x
48. Ohlsson K., Bjork P., Bergenfeldt M., Hageman R., Thompson R. C., Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990 348 6301 550 552 2-s2.0-0025225333 10.1038/348550a0 (Pubitemid 120015108)
49. Borden E. C., Chin P., Interleukin-6: a cytokine with potential diagnostic and therapeutic roles. Journal of Laboratory and Clinical Medicine 1994 123 6 824 829 2-s2.0-0028450108 (Pubitemid 2103598)
50. Chai Z., Gatti S., Toniatti C., Poli V., Bartfai T., Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1 β: a study on IL- 6-deficient mice. Journal of Experimental Medicine 1996 183 1 311 316 2-s2.0-0030058649 10.1084/jem.183.1.311 (Pubitemid 26028773)
51. Kopf M., Baumann H., Freer G., Freudenberg M., Lamers M., Kishimoto T., Zinkernagel R., Bluethmann H., Köhler G., Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994 368 6469 339 342 2-s2.0-0028328436 10.1038/368339a0 (Pubitemid 24104268)
52. Nijsten M. W. N., Hack C. E., Helle M., Ten Duis H. J., Klasen H. J., Aarden L. A., Interleukin-6 and its relation to the humoral immune response and clinical parameters in burned patients. Surgery 1991 109 6 761 767 2-s2.0-0025916516
53. Papanicolaou D. A., Wilder R. L., Manolagas S. C., Chrousos G. P., The pathophysiologic roles of interleukin-6 in human disease. Annals of Internal Medicine 1998 128 2 127 137 2-s2.0-0031963046 (Pubitemid 28053135)
54. Park J. Y., Pillinger M. H., Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bulletin of the NYU hospital for joint diseases 2007 65 supplement 1 S4 S10 2-s2.0-35748979444
55. Petersen A. M. W., Pedersen B. K., The anti-inflammatory effect of exercise. Journal of Applied Physiology 2005 98 4 1154 1162 2-s2.0-15444374348 10.1152/japplphysiol.00164.2004 (Pubitemid 40396484)
56. Scheller J., Rose-John S., Interleukin-6 and its receptor: from bench to bedside. Medical Microbiology and Immunology 2006 195 4 173 183 2-s2.0-33750166463 10.1007/s00430-006-0019-9 (Pubitemid 44600378)
57. Schindler R., Mancilla J., Endres S., Ghorbani R., Clark S. C., Dinarello C. A., Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990 75 1 40 47 2-s2.0-0025176658 (Pubitemid 20031487)
58. Steensberg A., Fischer C. P., Keller C., Møller K., Pedersen B. K., IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. American Journal of Physiology 2003 285 2 E433 E437 2-s2.0-0041846867 (Pubitemid 36899719)
59. Tilg H., Dinarello C. A., Mier J. W., IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunology Today 1997 18 9 428 432 2-s2.0-0030823183 10.1016/S0167-5699(97)01103-1 (Pubitemid 27381984)
60. Tilg H., Trehu E., Atkins M. B., Dinarello C. A., Mier J. W., Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994 83 1 113 118 2-s2.0-0028031990 (Pubitemid 24016522)
61. van der Poll T., Levi M., Hack C. E., Ten Cate H., Van Deventer S. J. H., Eerenberg A. J. M., De Groot E. R., Jansen J., Gallati H., Büller H. R., Ten Cate J. W., Aarden L. A., Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. Journal of Experimental Medicine 1994 179 4 1253 1259 2-s2.0-0028323245 (Pubitemid 24091784)
62. Xiao L. Z., Topley N., Ito T., Phillips A., Interleukin-6 regulation of transforming growth factor (TGF)- β receptor compartmentalization and turnover enhances TGF- β 1 signaling. The Journal of Biological Chemistry 2005 280 13 12239 12245 2-s2.0-16844377774 10.1074/jbc.M413284200
63. Rincon M., Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends in Immunology 2012 33 11 571 577
64. Bonecchi R., Bianchi G., Bordignon P. P., D'Ambrosio D., Lang R., Borsatti A., Sozzani S., Allavena P., Gray P. A., Mantovani A., Sinigaglia F., Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. Journal of Experimental Medicine 1998 187 1 129 134 2-s2.0-0031963014 10.1084/jem.187.1.129 (Pubitemid 28044828)
65. Estaquier J., Idziorek T., Zou W., Emilie D., Farber C.-M., Bourez-J. M., Ameisen J. C., T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons. Journal of Experimental Medicine 1995 182 6 1759 1767 2-s2.0-0028839280 10.1084/jem.182.6.1759
66. Puccetti P., Belladonna M. L., Grohmann U., Effects of IL-12 and IL-23 on antigen-presenting cells at the interface between innate and adaptive immunity. Critical Reviews in Immunology 2002 22 5-6 373 390 2-s2.0-0037655006 (Pubitemid 36548950)
67. Trinchieri G., Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature Reviews Immunology 2003 3 2 133 146 2-s2.0-0037313578 10.1038/nri1001 (Pubitemid 37328691)
68. Boehm U., Klamp T., Groot M., Howard J. C., Cellular responses to interferon-gamma. Annual Review of Immunology 1997 15 749 795
69. Calandra T., Baumgartner J.-D., Grau G. E., Wu M.-M., Lambert P.-H., Schellekens J., Verhoef J., Glauser M. P., Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon- and interferon- γ in the serum of patients with septic shock. Journal of Infectious Diseases 1990 161 5 982 987 2-s2.0-0025266645 (Pubitemid 20148336)
70. Flohé S. B., Agrawal H., Flohé S., Rani M., Bangen J. M., Schade F. U., Diversity of interferon γ and granulocyte-macrophage colony-stimulating factor in restoring immune dysfunction of dendritic cells and macrophages during polymicrobial sepsis. Molecular Medicine 2008 14 5-6 247 256 2-s2.0-44649084235 10.2119/2007-00120.Flohe (Pubitemid 351785697)
71. Leentjens J., Kox M., Koch R. M., Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. American Journal of Respiratory and Critical Care Medicine 2012 186 9 838 845
72. Okamura H., Kashiwamura S., Tsutsui H., Regulation of interferon-gamma production by IL-12 and IL-18. Current Opinion in Immunology 1998 10 3 259 264 (Pubitemid 28286951)
73. Wheelock E. F., Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin. Science 1965 149 3681 310 311 2-s2.0-33845772515
74. Bernhagen J., Calandra T., Mitchell R. A., Martin S. B., Tracey K. J., Voelter W., Manogue K. R., Cerami A., Bucala R., MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993 365 6448 756 759 2-s2.0-0027442237 10.1038/365756a0 (Pubitemid 23339882)
75. Bernhagen J., Krohn R., Lue H., Gregory J. L., Zernecke A., Koenen R. R., Dewor M., Georgiev I., Schober A., Leng L., Kooistra T., Fingerle-Rowson G., Ghezzi P., Kleemann R., McColl S. R., Bucala R., Hickey M. J., Weber C., MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nature Medicine 2007 13 5 587 596 2-s2.0-34249066942 10.1038/nm1567 (Pubitemid 46828480)
76. Bucala R., Donnelly S. C., Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity 2007 26 3 281 285 2-s2.0-33947112486 10.1016/j.immuni.2007.03.005 (Pubitemid 46413914)
77. Calandra T., Bernhagen J., Metz C. N., Spiegel L. A., Bacher M., Donnelly T., Cerami A., Bucala R., MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995 377 6544 68 71 2-s2.0-0029143676 10.1038/377068a0
78. Calandra T., Bernhagen J., Mitchell R. A., Bucala R., The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. Journal of Experimental Medicine 1994 179 6 1895 1902 2-s2.0-0028305693 10.1084/jem.179.6.1895 (Pubitemid 24155670)
79. Calandra T., Echtenacher B., Le Roy D., Pugin J., Metz C. N., Hültner L., Heumann D., Männel D., Bucala R., Glauser M. P., Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nature Medicine 2000 6 2 164 170 2-s2.0-0001611329 10.1038/72262 (Pubitemid 30082360)
80. Calandra T., Roger T., Macrophage migration inhibitory factor: a regulator of innate immunity. Nature Reviews Immunology 2003 3 10 791 800 2-s2.0-0142259734 (Pubitemid 37328657)
81. Leng L., Wang W., Roger T., Merk M., Wuttke M., Calandra T., Bucala R., Glucocorticoid-induced MIF expression by human CEM T cells. Cytokine 2009 48 3 177 185 2-s2.0-70350020290 10.1016/j.cyto.2009.07.002
82. Merk M., Mitchell R. A., Endres S., Bucala R., D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family. Cytokine 2012 59 1 10 17 2-s2.0-84859540214 10.1016/j.cyto.2012.03.014
83. Mitchell R. A., Liao H., Chesney J., Fingerle-Rowsor G., Baugh J., David J., Bucala R., Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proceedings of the National Academy of Sciences of the United States of America 2002 99 1 345 350 2-s2.0-0037039308 10.1073/pnas.012511599 (Pubitemid 34060365)
84. Roger T., Chanson A., Knaup-Reymond M., Calandra T., Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. European Journal of Immunology 2005 35 12 3405 3413 2-s2.0-29744463898 10.1002/eji.200535413 (Pubitemid 43025521)
85. Malefyt R. D. W., Abrams J., Bennett B., Figdor C. G., de Vries J. E., Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. Journal of Experimental Medicine 1991 174 5 1209 1220 2-s2.0-0026094306
86. Fiorentino D. F., Zlotnik A., Mosmann T. R., Howard M., O'Garra A., IL-10 inhibits cytokine production by activated macrophages. The Journal of Immunology 1991 147 11 3815 3822 2-s2.0-0025889028
87. Latifi S. Q., O'Riordan M. A., Levine A. D., Interleukin-10 controls the onset of irreversible septic shock. Infection and Immunity 2002 70 8 4441 4446 2-s2.0-0036073338 10.1128/IAI.70.8.4441-4446.2002 (Pubitemid 34790955)
88. Seitz M., Loetscher P., Dewald B., Towbin H., Gallati H., Baggiolini M., Interleukin-10 differentially regulates cytokine inhibitor and chemokine release from blood mononuclear cells and fibroblasts. European Journal of Immunology 1995 25 4 1129 1132 2-s2.0-0028942737
89. Blobe G. C., Schiemann W. P., Lodish H. F., Role of transforming growth factor β in human disease. The New England Journal of Medicine 2000 342 18 1350 1358 2-s2.0-0034604110 10.1056/NEJM200005043421807 (Pubitemid 30408720)
90. Bogdan C., Nathan C., Modulation of macrophage function by transforming growth factor β interleukin-4, and interleukin-10. Annals of the New York Academy of Sciences 1993 685 713 739 2-s2.0-0027248910 (Pubitemid 23238554)
91. Marie C., Cavaillon J. M., Losser M. R., Elevated levels of circulating transforming growth factor-beta 1 in patients with the sepsis syndrome. Annals of internal medicine 1996 125 6 520 521 2-s2.0-0030587266
92. Pellacani A., Wiesel P., Razavi S., Vasilj V., Feinberg M. W., Chin M. T., Reeves R., Perrella M. A., Down-regulation of high mobility group-I(Y) protein contributes to the inhibition of nitric-oxide synthase 2 by transforming growth factor- β 1. The Journal of Biological Chemistry 2001 276 2 1653 1659 2-s2.0-0035847093 10.1074/jbc.M008170200 (Pubitemid 32096602)
93. Sporn M. B., Roberts A. B., Transforming growth factor- β: multiple actions and potential clinical applications. Journal of the American Medical Association 1989 262 7 938 941 2-s2.0-0024322865 (Pubitemid 19208953)
94. Turner M., Chantry D., Katsikis P., Berger A., Brennan F. M., Feldmann M., Induction of the interleukin 1 receptor antagonist protein by transforming growth factor- β European Journal of Immunology 1991 21 7 1635 1639 2-s2.0-0025814912
95. Opal S. M., DePalo V. A., Anti-inflammatory cytokines. Chest 2000 117 4 1162 1172 2-s2.0-0034090602 (Pubitemid 30228378)
96. Seder R. A., Paul W. E., Davis M. M., de st. Groth B. F., The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. Journal of Experimental Medicine 1992 176 4 1091 1098 2-s2.0-0026712313
97. Cavaillon J.-M., Munoz C., Fitting C., Misset B., Carlet J., Circulating cytokines: the tip of the iceberg? Circulatory Shock 1992 38 2 145 152 2-s2.0-0026648849
98. Blackwell T. S., Christman J. W., Sepsis and cytokines: current status. British Journal of Anaesthesia 1996 77 1 110 117 2-s2.0-0029944101 (Pubitemid 26229918)
99. Aikawa N., Cytokine storm in the pathogenesis of multiple organ dysfunction syndrome associated with surgical insults. Nippon Geka Gakkai Zasshi 1996 97 9 771 777 2-s2.0-0030236705
100. Junger W. G., Hoyt D. B., Liu F. C., Loomis W. H., Coimbra R., Immunosuppression after endotoxin shock: the result of multiple anti-inflammatory factors. Journal of Trauma 1996 40 5 702 709 2-s2.0-0029999112 (Pubitemid 26142750)
101. Tang B. M., Huang S. J., McLean A. S., Genome-wide transcription profiling of human sepsis: a systematic review. Critical Care 2010 14 6, article R237 2-s2.0-78650624395 10.1186/cc9392
102. Hack C. E., Aarden L. A., Thijs L. G., Role of cytokines in sepsis. Advances in Immunology 1997 66 101 195 2-s2.0-0030963768 (Pubitemid 27430942)
103. van der Poll T., van Deventer S. J. H., Cytokines and anticytokines in the pathogenesis of sepsis. Infectious Disease Clinics of North America 1999 13 2 413 426 2-s2.0-0032997973 10.1016/S0891-5520(05)70083-0 (Pubitemid 29248753)
104. Dinarello C., Arend W., Sims J., IL-1 family nomenclature. Nature Immunology 2010 11 11, article 973
105. Kapoor M., Martel-Pelletier J., Lajeunesse D., Pelletier J., Fahmi H., Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nature Reviews Rheumatology 2011 7 1 33 42 2-s2.0-78650983649 10.1038/nrrheum.2010.196
106. Lewis M., Tartaglia L. A., Lee A., Bennett G. L., Rice G. C., Wong G. H. W., Chen E. Y., Goeddel D. V., Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proceedings of the National Academy of Sciences of the United States of America 1991 88 7 2830 2834 2-s2.0-0025756330 (Pubitemid 21916513)
107. Bhatia M., Moochhala S., Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. Journal of Pathology 2004 202 2 145 156 2-s2.0-1142299409 10.1002/path.1491 (Pubitemid 38208651)
108. Selby P., Hobbs S., Viner C., Jackson E., Jones A., Newell D., Calvert A. H., McElwain T., Fearon K., Humphreys J., Shiga T., Tumour necrosis factor in man: clinical and biological observations. British Journal of Cancer 1987 56 6 803 808 2-s2.0-0023600858 (Pubitemid 18048357)
109. Sherman M. L., Spriggs D. R., Arthur K. A., Imamura K., Frei E. III, Kufe D. W., Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. Journal of Clinical Oncology 1988 6 2 344 350 2-s2.0-0023863335 (Pubitemid 18065941)
110. van der Poll T., Buller H. R., ten Cate H., Wortel C. H., Bauer K. A., van Deventer S. J. H., Hack C. E., Sauerwein H. P., Rosenberg R. D., ten Cate J. W., Activation of coagulation after administration of tumor necrosis factor to normal subjects. The New England Journal of Medicine 1990 322 23 1622 1627 2-s2.0-0025303041 (Pubitemid 20171585)
111. Tewari A., Buhles W. C. Jr., Starnes H. F. Jr., Preliminary report: effects of interleukin-1 on platelet counts. The Lancet 1990 336 8717 712 714 2-s2.0-0025108171 (Pubitemid 20309130)
112. Dinarello C. A., Interleukin-1 and interleukin-1 antagonism. Blood 1991 77 8 1627 1652 2-s2.0-0025777448
113. Okusawa S., Gelfand J. A., Ikejima T., Connolly R. J., DInarello C. A., Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. The Journal of Clinical Investigation 1988 81 4 1162 1172 2-s2.0-0344140225
114. Cannon J. G., Tompkins R. G., Gelfand J. A., Michie H. R., Stanford G. G., Van Der Meer J. W. M., Endres S., Lonnemann G., Corsetti J., Chernow B., Wilmore D. W., Wolff S. M., Burke J. F., Dinarello C. A., Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. Journal of Infectious Diseases 1990 161 1 79 84 2-s2.0-0025017232 (Pubitemid 20021861)
115. Hesse D. G., Tracey K. J., Fong Y., Manogue K. R., Palladino M. A. Jr., Cerami A., Shires G. T., Lowry S. F., Cytokine appearance in human endotoxemia and primate bacteremia. Surgery Gynecology and Obstetrics 1988 166 2 147 153 2-s2.0-0023912918
116. Michie H. R., Manogue K. R., Spriggs D. R., Revhaug A., O'Dwyer S., Dinarello C. A., Cerami A., Wolff S. M., Wilmore D. W., Detection of circulating tumor necrosis factor after endotoxin administration. The New England Journal of Medicine 1988 318 23 1481 1486 2-s2.0-0023893831
117. Suffredini A. F., Fromm R. E., Parker M. M., Brenner M., Kovacs J. A., Wesley R. A., Parrillo J. E., The cardiovascular response of normal humans to the administration of endotoxin. The New England Journal of Medicine 1989 321 5 280 287 2-s2.0-0024342856 (Pubitemid 19193802)
118. Fahlman C., Jacobsen F. W., Veiby O. P., McNiece I. K., Blomhoff H. K., Jacobsen S. E. W., Tumor necrosis factor- (TNF-) potently enhances in vitro macrophage production from primitive murine hematopoietic progenitor cells in combination with stem cell factor and interleukin-7: novel stimulatory role of p55 TNF receptors. Blood 1994 84 5 1528 1533 2-s2.0-0028168343
119. Conte D., Holcik M., Lefebvre C. A., LaCasse E., Picketts D. J., Wright K. E., Korneluk R. G., Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival. Molecular and Cellular Biology 2006 26 2 699 708 2-s2.0-30744452261 10.1128/MCB.26.2.699-708.2006 (Pubitemid 43090921)
120. Nakae H., Endo S., Inada K., Takakuwa T., Kasai T., Changes in adhesion molecule levels in sepsis. Research Communications in Molecular Pathology and Pharmacology 1996 91 3 329 338 (Pubitemid 26149053)
121. Shimaoka M., Park E. J., Advances in understanding sepsis. European Journal of Anaesthesiology 2008 25 42 146 153 2-s2.0-43149112066 10.1017/S0265021507003389 (Pubitemid 351643064)
122. Spinas G. A., Keller U., Brockhaus M., Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. The Journal of Clinical Investigation 1992 90 2 533 536 2-s2.0-0026737258
123. Kuhns D. B., Alvord W. G., Gallin J. I., Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. Journal of Infectious Diseases 1995 171 1 145 152 2-s2.0-0028873514
124. Ertel W., Scholl F. A., Gallati H., Bonaccio M., Schildberg F.-W., Trentz O., Rotstein O. D., Marshall J., Christou N. V., Sautner T., Increased release of soluble tumor necrosis factor receptors into blood during clinical sepsis. Archives of Surgery 1994 129 12 1330 1337 2-s2.0-0028148694 (Pubitemid 24374479)
125. Gardlund B., Sjolin J., Nilsson A., Roll M., Wickerts C.-J., Wretlind B., Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. Journal of Infectious Diseases 1995 172 1 296 301 2-s2.0-0029038728
126. Goldie A. S., Fearon K. C. H., Ross J. A., Barclay G. R., Jackson R. E., Grant I. S., Ramsay G., Blyth A. S., Howie J. C., Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. Journal of the American Medical Association 1995 274 2 172 177 2-s2.0-0028997703
127. Fischer E., Marano M. A., Van Zee K. J., Rock C. S., Hawes A. S., Thompson W. A., DeForge L., Kenney J. S., Remick D. G., Bloedow D. C., Thompson R. C., Lowry S. F., Moldawer L. L., Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. The Journal of Clinical Investigation 1992 89 5 1551 1557 2-s2.0-0026772736
128. Creasey A. A., Stevens P., Kenney J., Allison A. C., Warren K., Catlett R., Hinshaw L., Taylor F. B. Jr., Endotoxin and cytokine profile in plasma of baboons challenged with lethal and sublethal Escherichia coli. Circulatory Shock 1991 33 2 84 91 2-s2.0-0026065417
129. Damas P., Ledoux D., Nys M., Vrindts Y., De Groote D., Franchimont P., Lamy M., Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Annals of Surgery 1992 215 4 356 362 2-s2.0-0026575846
130. Cruickshank A. M., Fraser W. D., Burns H. J. G., van Damme J., Shenkin A., Response of serum interleukin-6 in patients undergoing elective surgery of varying severity. Clinical Science 1990 79 2 161 165 2-s2.0-0025334161 (Pubitemid 20218956)
131. Hoch R. C., Rodriguez R., Manning T., Bishop M., Mead P., Shoemaker W. C., Abraham E., Effects of accidental trauma on cytokine and endotoxin production. Critical Care Medicine 1993 21 6 839 845 2-s2.0-0027302517 (Pubitemid 23173020)
132. Hack C. E., De Groot E. R., Felt-Bersma R. J. F., Nuijens J. H., van Schijndel R. J. M. S., Eerenberg-Belmer A. J. M., Thijs L. G., Aarden L. A., Increased plasma levels of interleukin-6 in sepsis. Blood 1989 74 5 1704 1710 2-s2.0-0024451525 (Pubitemid 19251549)
133. Borrelli E., Roux-Lombard P., Grau G. E., Girardin E., Ricou B., Dayer J., Suter P. M., Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Critical Care Medicine 1996 24 3 392 397 2-s2.0-0029997657 10.1097/00003246-199603000-00006 (Pubitemid 26097830)
134. Waage A., Brandtzaeg P., Halstensen A., Kierulf P., Espevik T., The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. Journal of Experimental Medicine 1989 169 1 333 338 2-s2.0-0024529891 (Pubitemid 19035565)
135. Preiser J., Schmartz D., van der Linden P., Content J., Vanden Bussche P., Buurman W., Sebald W., Dupont E., Pinsky M. R., Vincent J., Interleukin-6 administration has no acute hemodynamic or hematologic effect in the dog. Cytokine 1991 3 1 1 4 2-s2.0-0025931496
136. Kushner I., Rzewnicki D. L., The acute phase response: general aspects. Bailliere's Clinical Rheumatology 1994 8 3 513 530 2-s2.0-0028123123 10.1016/S0950-3579(05)80113-X (Pubitemid 24256889)
137. Cuzzocrea S., Sautebin L., De Sarro G., Role of IL-6 in the pleurisy and lung injury caused by carrageenan. The Journal of Immunology 1999 163 9 5094 5104 (Pubitemid 29501279)
138. Cuzzocrea S., De Sarro G., Costantino G., Mazzon E., Laurà R., Ciriaco E., De Sarro A., Caputi A. P., Role of interleukin-6 in a non-septic shock model induced by zymosan. European Cytokine Network 1999 10 2 191 203 2-s2.0-0032782850 (Pubitemid 29332775)
139. Pathan N., Hemingway C. A., Alizadeh A. A., Stephens A. C., Boldrick J. C., Oragui E. E., McCabe C., Welch S. B., Whitney A., O'Gara P., Nadel S., Relman D. A., Harding S. E., Levin M., Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. The Lancet 2004 363 9404 203 209 2-s2.0-9144265427 10.1016/S0140-6736(03)15326-3 (Pubitemid 38114718)
140. Yoshizawa K., Naruto M., Ida N., Injection time of interleukin-6 determines fatal outcome in experimental endotoxin shock. Journal of Interferon and Cytokine Research 1996 16 12 995 1000 2-s2.0-0030452965 (Pubitemid 26427030)
141. Xing Z., Gauldie J., Cox G., Baumann H., Jordana M., Lei X., Achong M. K., IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. The Journal of Clinical Investigation 1998 101 2 311 320 2-s2.0-0032518415 (Pubitemid 28067327)
142. Remick D. G., Bolgos G., Copeland S., Siddiqui J., Role of interleukin-6 in mortality from and physiologic response to sepsis. Infection and Immunity 2005 73 5 2751 2757 2-s2.0-17644401778 10.1128/IAI.73.5.2751-2757.2005 (Pubitemid 40570341)
143. Jones L. L., Vignali D. A. A., Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily. Immunologic Research 2011 51 1 5 14 2-s2.0-80053573336 10.1007/s12026-011-8209-y
144. Steinhauser M. L., Hogaboam C. M., Lukacs N. W., Strieter R. M., Kunkel S. L., Multiple roles for IL-12 in a model of acute septic peritonitis. The Journal of Immunology 1999 162 9 5437 5443 2-s2.0-0033136310 (Pubitemid 29307153)
145. Zisman D. A., Kunkel S. L., Strieter R. M., Gauldie J., Tsai W. C., Bramson J., Wilkowski J. M., Bucknell K. A., Standiford T. J., Anti-interleukin-12 therapy protects mice in lethal endotoxemia but impairs bacterial clearance in murine Escherichia coli peritoneal sepsis. Shock 1997 8 5 349 356 2-s2.0-0031264674 (Pubitemid 127654348)
146. Jansen P. M., Kraan T. C. T. M. V., de Jong I. W., van Mierlo G., Wijdenes J., Chang A. A., Aarden L. A., Taylor F. B. Jr., Hack C. E., Release of interleukin-12 in experimental Escherichia coli septic shock in baboons: relation to plasma levels of interleukin-10 and interferon- γ Blood 1996 87 12 5144 5151 2-s2.0-0029953218 (Pubitemid 26189855)
147. Moreno S. E., Alves-Filho J. C., Alfaya T. M., da Silva J. S., Ferreira S. H., Liew F. Y., IL-12, but not IL-18, is critical to neutrophil activation and resistance to polymicrobial sepsis induced by cecal ligation and puncture. The Journal of Immunology 2006 177 5 3218 3224 2-s2.0-33747753164 (Pubitemid 44277840)
148. Weighardt H., Heidecke C., Westerholt A., Emmanuilidis K., Maier S., Veit M., Gerauer K., Matevossian E., Ulm K., Siewert J., Holzmann B., Impaired monocyte IL-12 production before surgery as a predictive factor for the lethal outcome of postoperative sepsis. Annals of Surgery 2002 235 4 560 567 2-s2.0-0036204859 10.1097/00000658-200204000-00015 (Pubitemid 34258356)
149. Stanilova S. A., Karakolev Z. T., Dimov G. S., Dobreva Z. G., Miteva L. D., Slavov E. S., Stefanov C. S., Stanilov N. S., High interleukin 12 and low interleukin 10 production after in vitro stimulation detected in sepsis survivors. Intensive Care Medicine 2005 31 3 401 407 2-s2.0-23044477180
150. Wu H., Shih C., Lin C., Hua C., Chuang D., Serial increase of IL-12 response and human leukocyte antigen-DR expression in severe sepsis survivors. Critical Care 2011 15 5, article R224 2-s2.0-80054968884 10.1186/cc10464
151. Wang Z., Reiner S. L., Zheng S., Dalton D. K., Locksley R. M., CD4+ effector cells default to the Th2 pathway in interferon γ -deficient mice infected with Leishmania major. Journal of Experimental Medicine 1994 179 4 1367 1371 2-s2.0-0028326103 (Pubitemid 24091797)
152. Huang S., Hendriks W., Althage A., Hemmi S., Bluethmann H., Kamijo R., Vilcek J., Zinkernagel R. M., Aguet M., Immune response in mice that lack the interferon- γ receptor. Science 1993 259 5102 1742 1745 2-s2.0-0027464928 (Pubitemid 23114659)
153. Cooper A. M., Dalton D. K., Stewart T. A., Griffin J. P., Russell D. G., Orme I. M., Disseminated tuberculosis in interferon γ gene-disrupted mice. Journal of Experimental Medicine 1993 178 6 2243 2247 2-s2.0-0027482327 10.1084/jem.178.6.2243 (Pubitemid 23344885)
154. Müller U., Steinhoff U., Reis L. F. L., Hemmi S., Pavlovic J., Zinkernagel R. M., Aguet M., Functional role of type I and type II interferons in antiviral defense. Science 1994 264 5167 1918 1921 2-s2.0-0028070714 (Pubitemid 24245635)
155. Heinzel F. P., The role of IFN- γ in the pathology of experimental endotoxemia. The Journal of Immunology 1990 145 9 2920 2924 2-s2.0-0025134961 (Pubitemid 20382561)
156. Car B. D., Eng V. M., Schnyder B., Ozmen L., Huang S., Gallay P., Heumann D., Aguet M., Ryffel B., Interferon γ receptor deficient mice are resistant to endotoxic shock. Journal of Experimental Medicine 1994 179 5 1437 1444 2-s2.0-0028222122 (Pubitemid 24129561)
157. Munoz C., Carlet J., Fitting C., Misset B., Bleriot J.-P., Cavaillon J.-M., Dysregulation of in vitro cytokine production by monocytes during sepsis. The Journal of Clinical Investigation 1991 88 5 1747 1754 2-s2.0-0025748883
158. Ferguson N. R., Galley H. F., Webster N. R., T helper cell subset ratios in patients with severe sepsis. Intensive Care Medicine 1999 25 1 106 109 2-s2.0-0032983831 10.1007/s001340050795 (Pubitemid 29126723)
159. Rich A. R., Lewis M. R., The nature of allergy in tuberculosis as revealed by tissue culture studies. Bulletin of the Johns Hopkins Hospital 1932 50 115 131
160. Calandra T., Spiegel L. A., Metz C. N., Bucala R., Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. Proceedings of the National Academy of Sciences of the United States of America 1998 95 19 11383 11388 2-s2.0-0032530821 10.1073/pnas.95.19.11383 (Pubitemid 28450137)
161. Merk M., Baugh J., Zierow S., Leng L., Pal U., Lee S. J., Ebert A. D., Mizue Y., Trent J. O., Mitchell R., Nickel W., Kavathas P. B., Bernhagen J., Bucala R., The Golgi-associated protein p115 mediates the secretion of macrophage migration inhibitory factor. The Journal of Immunology 2009 182 11 6896 6906 2-s2.0-67449126820 10.4049/jimmunol.0803710
162. Roger T., David J., Glauser M. P., Calandra T., MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 2001 414 6866 920 924 2-s2.0-0035924325 10.1038/414920a (Pubitemid 34024744)
163. Shi X., Leng L., Wang T., Wang W., Du X., Li J., McDonald C., Chen Z., Murphy J. W., Lolis E., Noble P., Knudson W., Bucala R., CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 2006 25 4 595 606 2-s2.0-33749508911 10.1016/j.immuni.2006.08.020 (Pubitemid 44529040)
164. Leng L., Metz C. N., Fang Y., Xu J., Donnelly S., Baugh J., Delohery T., Chen Y., Mitchell R. A., Bucala R., MIF signal transduction initiated by binding to CD74. Journal of Experimental Medicine 2003 197 11 1467 1476 2-s2.0-12444285441 10.1084/jem.20030286 (Pubitemid 36686708)
165. Rossi A. G., Haslett C., Hirani N., Greening A. P., Rahman I., Metz C. N., Bucala R., Donnelly S. C., Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF): potential role in asthma. The Journal of Clinical Investigation 1998 101 12 2869 2874 2-s2.0-0032525889 (Pubitemid 28294596)
166. Mikulowska A., Metz C. N., Bucala R., Holmdahl R., Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-lnduced arthritis in mice. The Journal of Immunology 1997 158 11 5514 5517 2-s2.0-0031154718 (Pubitemid 127681261)
167. Lin S., Yu X., Chen Y., Huang X. R., Metz C., Bucala R., Lau C., Lan H. Y., De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circulation Research 2000 87 12 1202 1208 2-s2.0-0034623802
168. de Jong Y. P., Abadia-Molina A. C., Satoskar A. R., Development of chronic colitis is dependent on the cytokine MIF. Nature Immunology 2001 2 11 1061 1066 (Pubitemid 33069502)
169. Al-Abed Y., Dabideen D., Aljabari B., Valster A., Messmer D., Ochani M., Tanovic M., Ochani K., Bacher M., Nicoletti F., Metz C., Pavlov V. A., Miller E. J., Tracey K. J., ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. The Journal of Biological Chemistry 2005 280 44 36541 36544 2-s2.0-27744530222 10.1074/jbc.C500243200 (Pubitemid 41587728)
170. Bozza M., Satoskar A. R., Lin G., Lu B., Humbles A. A., Gerard C., David J. R., Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. Journal of Experimental Medicine 1999 189 2 341 346 2-s2.0-0033579884 10.1084/jem.189.2.341 (Pubitemid 29063255)
171. Matsuda N., Nishihira J., Takahashi Y., Kemmotsu O., Hattori Y., Role of macrophage migration inhibitory factor in acute lung injury in mice with acute pancreatitis complicated by endotoxemia. American Journal of Respiratory Cell and Molecular Biology 2006 35 2 198 205 2-s2.0-33746853916 10.1165/rcmb.2005- 0272OC (Pubitemid 44175319)
172. Kobayashi S., Nishihira J., Watanabe S., Todo S., Prevention of lethal acute hepatic failure by antimacrophage migration inhibitory factor antibody in mice treated with bacille Calmette-Guerin and lipopolysaccharide. Hepatology 1999 29 6 1752 1759 2-s2.0-0033057755 10.1002/hep.510290610 (Pubitemid 29247049)
173. Garner L. B., Willis M. S., Carlson D. L., DiMaio J. M., White M. D., White D. J., Adams G. A. IV, Horton J. W., Giroir B. P., Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor. American Journal of Physiology 2003 285 6 H2500 H2509 2-s2.0-0344009602 (Pubitemid 37443067)
174. Miller E. J., Li J., Leng L., McDonald C., Atsumi T., Bucala R., Young L. H., Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 2008 451 7178 578 582 2-s2.0-38749137749 10.1038/nature06504 (Pubitemid 351186266)
175. Merk M., Zierow S., Leng L., Das R., Du X., Schulte W., Fan J., Lue H., Chen Y., Xiong H., Chagnon F., Bernhagen J., Lolis E., Mor G., Lesur O., Bucala R., The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF). Proceedings of the National Academy of Sciences of the United States of America 2011 108 34 E577 E585 2-s2.0-80052143498 10.1073/pnas.1102941108
176. Beishuizen A., Thijs L. G., Haanen C., Vermes I., Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness. Journal of Clinical Endocrinology and Metabolism 2001 86 6 2811 2816 2-s2.0-0034966944 10.1210/jc.86.6.2811 (Pubitemid 32545744)
177. Brenner T., Hofer S., Rosenhagen C., Steppan J., Lichtenstern C., Weitz J., Bruckner T., Lukic I. K., Martin E., Bierhaus A., Hoffmann U., Weigand M. A., Macrophage migration inhibitory factor (MIF) and manganese superoxide dismutase (MnSOD) as early predictors for survival in patients with severe sepsis or septic shock. Journal of Surgical Research 2010 164 1 e163 e171 2-s2.0-77958086269 10.1016/j.jss.2010.05.004
178. Yende S., Angus D. C., Kong L., Kellum J. A., Weissfeld L., Ferrell R., Finegold D., Carter M., Leng L., Peng Z., Bucala R., The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia. The FASEB Journal 2009 23 8 2403 2411 2-s2.0-68849109968 10.1096/fj.09-129445
179. Renner P., Roger T., Bochud P., Sprong T., Sweep F. C. G. J., Bochud M., Faust S. N., Haralambous E., Betts H., Chanson A., Reymond M. K., Mermel E., Erard V., Van Deuren M., Read R. C., Levin M., Calandra T., A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease. The FASEB Journal 2012 26 2 907 916 2-s2.0-84856528328 10.1096/fj.11-195065
180. Doernberg S., Schaaf B., Dalhoff K., Leng L., Beitin A., Quagliarello V., Bucala R., Association of macrophage migration inhibitory factor (MIF) polymorphisms with risk of meningitis from Streptococcus pneumoniae. Cytokine 2011 53 3 292 294 2-s2.0-79251604801 10.1016/j.cyto.2010.12.010
181. Awandare G. A., Martinson J. J., Were T., Ouma C., Davenport G. C., Ong'Echa J. M., Wang W., Leng L., Ferrell R. E., Bucala R., Perkins D. J., MIF (Macrophage Migration Inhibitory Factor) promoter polymorphisms and susceptibility to severe malarial anemia. Journal of Infectious Diseases 2009 200 4 629 637 2-s2.0-69149100364 10.1086/600894
182. Howard M., Muchamuel T., Andrade S., Menon S., Interleukin 10 protects mice from lethal endotoxemia. Journal of Experimental Medicine 1993 177 4 1205 1208 2-s2.0-0027408695 (Pubitemid 23097411)
183. Howard M., O'Garra A., Biological properties of interleukin 10. Journal of Clinical Immunology 1992 12 4 239 247
184. Song G. Y., Chung C., Chaudry I. H., Ayala A., What is the role of interleukin 10 in polymicrobial sepsis: anti-inflammatory agent or immunosuppressant? Surgery 1999 126 2 378 383 2-s2.0-0032853454 10.1016/S0039-6060(99)70180-7 (Pubitemid 29382806)
185. van der Poll T., Marchant A., Buurman W. A., Berman L., Keogh C. V., Lazarus D. D., Nguyen L., Goldman M., Moldawer L. L., Lowry S. F., Endogenous IL-10 protects mice from death during septic peritonitis. The Journal of Immunology 1995 155 11 5397 5401 2-s2.0-0028970736 (Pubitemid 3015364)
186. Zeng L., Gu W., Chen K., Jiang D., Zhang L., Du D., Hu P., Liu Q., Huang S., Jiang J., Clinical relevance of the interleukin 10 promoter polymorphisms in Chinese Han patients with major trauma: genetic association studies. Critical Care 2009 13 6, article R188 2-s2.0-77951644924
187. Gilbert K. M., Thoman M., Bauche K., Pham T., Weigle W. O., Transforming growth factor- β 1 induces antigen-specific unresponsiveness in naive T cells. Immunological Investigations 1997 26 4 459 472 2-s2.0-0030788348 (Pubitemid 27305215)
188. Wan Y. Y., Flavell R. A., TGF- β and regulatory T cell in immunity and autoimmunity. Journal of Clinical Immunology 2008 28 6 647 659 2-s2.0-56649118964 10.1007/s10875-008-9251-y
189. Randow F., Syrbe U., Meisel C., Krausch D., Zuckermann H., Platzer C., Volk-H. D., Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor β Journal of Experimental Medicine 1995 181 5 1887 1892 2-s2.0-0028906220
190. Perrella M. A., Hsieh C. M., Lee W. S., Arrest of endotoxin-induced hypotension by transforming growth factor beta1. Proceedings of the National Academy of Sciences of the United States of America 1996 93 5 2054 2059 (Pubitemid 26079879)
191. Pender B. S., Transforming growth factor β 1 alters rat peritoneal macrophage mediator production and improves survival during endotoxic shock. European Cytokine Network 1996 7 2 137 142 2-s2.0-0029913880 (Pubitemid 26144551)
192. Zanotti S., Kumar A., Kumar A., Cytokine modulation in sepsis and septic shock. Expert Opinion on Investigational Drugs 2002 11 8 1061 1075 2-s2.0-0036045390 10.1517/13543784.11.8.1061
193. Knapp S., Thalhammer F., Locker G. J., Laczika K., Hollenstein U., Frass M., Winkler S., Stoiser B., Wilfing A., Burgmann H., Prognostic value of MIP-1 TGF- β 2, sELAM-1, and sVCAM-1 in patients with gram-positive sepsis. Clinical Immunology and Immunopathology 1998 87 2 139 144 2-s2.0-0031860205 10.1006/clin.1998.4523 (Pubitemid 28235697)
194. Kumar A., Kumar A., Paladugu B., Mensing J., Parrillo J. E., Transforming growth factor- β 1 blocks in vitro cardiac myocyte depression induced by tumor necrosis factor- interleukin-1 β and human septic shock serum. Critical Care Medicine 2007 35 2 358 364 2-s2.0-33846433158 10.1097/01.CCM. 0000254341.87098.A4 (Pubitemid 46148522)
195. Zamorano J., Wang H. Y., Wang L., Pierce J. H., Keegan A. D., IL-4 protects cells from apoptosis via the insulin receptor substrate pathway and a second independent signaling pathway. The Journal of Immunology 1996 157 11 4926 4934 2-s2.0-0030444051 (Pubitemid 126449569)
196. Yanagida M., Fukamachi H., Ohgami K., Kuwaki T., Ishii H., Uzumaki H., Amano K., Tokiwa T., Mitsui H., Saito H., Iikura Y., Ishizaka T., Nakahata T., Effects of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Blood 1995 86 10 3705 3714 2-s2.0-0028785274
197. Lutz M. B., Schnare M., Menges M., Rössner S., Röllinghoff M., Schuler G., Gessner A., Differential functions of IL-4 receptor types I and II for dendritic cell maturation and IL-12 production and their dependency on GM-CSF. The Journal of Immunology 2002 169 7 3574 3580 2-s2.0-0036786477
198. Baumhofer J. M., Beinhauer B. G., Wang J. E., Gene transfer with IL-4 and IL-13 improves survival in lethal endotoxemia in the mouse and ameliorates peritoneal macrophages immune competence. European Journal of Immunology 1998 28 2 610 615 (Pubitemid 28101738)
199. Hultgren O., Kopf M., Tarkowski A., Outcome of Staphylococcus aureus -triggered sepsis and arthritis in IL-4-deficient mice depends on the genetic background of the host. European Journal of Immunology 1999 29 8 2400 2405 (Pubitemid 29378108)
200. Wu H. P., Wu C. L., Chen C. K., The interleukin-4 expression in patients with severe sepsis. Journal of Critical Care 2008 23 4 519 524
201. Gu W., Zeng L., Zhang L., Jiang D., Du D., Hu P., Wang H., Liu Q., Huang S., Jiang J., Association of interleukin 4-589T/C Polymorphism with TH1 and TH2 bias and sepsis in chinese major trauma patients. Journal of Trauma 2011 71 6 1583 1587 2-s2.0-84355166810 10.1097/TA.0b013e3182115034
202. Fisher C. J. Jr., Opal S. M., Dhainaut J. F., Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Critical Care Medicine 1993 21 3 318 327 (Pubitemid 23097025)
203. Opal S. M., Fisher C. J. Jr., Dhainaut J. A., Vincent J., Brase R., Lowry S. F., Sadoff J. C., Slotman G. J., Levy H., Balk R. A., Shelly M. P., Pribble J. P., LaBrecque J. F., Lookabaugh J., Donovan H., Dubin H., Baughman R., Norman J., DeMaria E., Matzel K., Abraham E., Seneff M., Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Critical Care Medicine 1997 25 7 1115 1124 2-s2.0-0030877935 10.1097/00003246-199707000-00010 (Pubitemid 27310249)
204. Zeni F., Freeman B., Natanson C., Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Critical Care Medicine 1997 25 7 1095 1100 2-s2.0-0030746482 10.1097/00003246-199707000-00001 (Pubitemid 27310241)
205. Cohen J., Carlet J., INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor- in patients with sepsis. Critical Care Medicine 1996 24 9 1431 1440 2-s2.0-0029835023 (Pubitemid 26313741)
206. Parrish W. R., Gallowitsch-Puerta M., Czura C. J., Tracey K. J., Experimental therapeutic strategies for severe sepsis: mediators and mechanisms. Annals of the New York Academy of Sciences 2008 1144 210 236 2-s2.0-56649095996 10.1196/annals.1418.011
207. Ulloa L., Tracey K. J., The "cytokine profile": a code for sepsis. Trends in Molecular Medicine 2005 11 2 56 63 2-s2.0-13244288781 10.1016/j.molmed.2004.12.007 (Pubitemid 40193483)
208. Lubetsky J. B., Dios A., Han J., Aljabari B., Ruzsicska B., Mitchell R., Lolis E., Al-Abed Y., The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. The Journal of Biological Chemistry 2002 277 28 24976 24982 2-s2.0-0037067777 10.1074/jbc.M203220200 (Pubitemid 34951799)
209. Leng L., Chen L., Fan J., Greven D., Arjona A., Du X., Austin D., Kashgarian M., Yin Z., Huang X. R., Lan H. Y., Lolis E., Nikolic-Paterson D., Bucala R., A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in Lupus-Prone NZB/NZW F1 and MRL/lpr mice. The Journal of Immunology 2011 186 1 527 538 2-s2.0-79251539843 10.4049/jimmunol.1001767
210. Arjona A., Foellmer H. G., Town T., Leng L., McDonald C., Wang T., Wong S. J., Montgomery R. R., Fikrig E., Bucala R., Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. The Journal of Clinical Investigation 2007 117 10 3059 3066 2-s2.0-34948860191 10.1172/JCI32218 (Pubitemid 47529635)
211. Kerschbaumer R. J., Rieger M., Völkel D., Roy D. L., Roger T., Garbaraviciene J., Boehncke W., Müllberg J., Hoet R. M., Wood C. R., Antoine G., Thiele M., Savidis-Dacho H., Dockal M., Ehrlich H., Calandra T., Scheiflinger F., Neutralization of macrophage migration inhibitory factor (MIF) by fully human antibodies correlates with their specificity for the β -sheet structure of MIF. The Journal of Biological Chemistry 2012 287 10 7446 7455 2-s2.0-84857697372 10.1074/jbc.M111.329664
212. Hare A. A., Leng L., Gandavadi S., Du X., Cournia Z., Bucala R., Jorgensen W. L., Optimization of N-benzyl-benzoxazol-2-ones as receptor antagonists of macrophage migration inhibitory factor (MIF). Bioorganic and Medicinal Chemistry Letters 2010 20 19 5811 5814 2-s2.0-77957595054 10.1016/j.bmcl.2010.07.129
213. Kraemer S., Lue H., Zernecke A., Kapurniotu A., Andreetto E., Frank R., Lennartz B., Weber C., Bernhagen J., MIF-chemokine receptor interactions in atherogenesis are dependent on an N-loop-based 2-site binding mechanism. The FASEB Journal 2011 25 3 894 906 2-s2.0-79954573511 10.1096/fj.10-168559
214. Presneill J. J., Harris T., Stewart A. G., Cade J. F., Wilson J. W., A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. American Journal of Respiratory and Critical Care Medicine 2002 166 2 138 143 2-s2.0-0037099153 10.1164/rccm.2009005 (Pubitemid 34765447)
215. Rosenbloom A. J., Linden P. K., Dorrance A., Penkosky N., Cohen-Melamed M. H., Pinsky M. R., Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients. Chest 2005 127 6 2139 2150 2-s2.0-21844453227 10.1378/chest.127.6.2139
216. Polk H. C. Jr., Cheadle W. G., Livingston D. H., Rodriguez J. L., Starko K. M., Izu A. E., Jaffe H. S., Sonnenfeld G., A randomized prospective clinical trial to determine the efficacy of interferon- γ in severely injured patients. American Journal of Surgery 1992 163 2 191 196 2-s2.0-0027055454 10.1016/0002-9610(92)90099-D (Pubitemid 23059255)
217. Esmon C. T., The interactions between inflammation and coagulation. British Journal of Haematology 2005 131 4 417 430 2-s2.0-33644801469 10.1111/j.1365-2141.2005.05753.x (Pubitemid 43899639)
218. Esmon C. T., The protein C pathway. Chest 2003 124 supplement 3 26S 32S 2-s2.0-0141819138 (Pubitemid 37128433)
219. Neyrinck A. P., Liu K. D., Howard J. P., Matthay M. A., Protective mechanisms of activated protein C in severe inflammatory disorders. British Journal of Pharmacology 2009 158 4 1034 1047 2-s2.0-70350129236 10.1111/j.1476-5381.2009.00251.x
220. Vera P. L., Wolfe T. E., Braley A. E., Meyer-Siegler K. L., Thrombin induces macrophage migration inhibitory factor release and upregulation in urothelium: a possible contribution to bladder inflammation. PLoS ONE 2010 5 12 2-s2.0-79251480408 10.1371/journal.pone.0015904 e15904
221. Galley H. F., El Sakka N. E., Webster N. R., Lowes D. A., Cuthbertson B. H., Activated protein C inhibits chemotaxis and interleukin-6 release by human neutrophils without affecting other neutrophil functions. British Journal of Anaesthesia 2008 100 6 815 819 2-s2.0-44649103920 10.1093/bja/aen079 (Pubitemid 351774323)
222. Okajima K., Regulation of inflammatory responses by natural anticoagulants. Immunological Reviews 2001 184 258 274 2-s2.0-0035707639 10.1034/j.1600-065x.2001.1840123.x (Pubitemid 34123781)
223. Schmidt-Supprian M., Murphy C., White B., Lawler M., Kapurniotu A., Voelter W., Smith O., Bernhagen J., Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes. European Cytokine Network 2000 11 3 407 413 2-s2.0-0034456899 (Pubitemid 32268899)
224. Bilbault P., Lavaux T., Launoy A., Gaub M. P., Meyer N., Oudet P., Pottecher T., Jaeger A., Schneider F., Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients. Critical Care Medicine 2007 35 1 69 75 2-s2.0-33845917566 10.1097/01.CCM.0000251133. 26979.F4 (Pubitemid 46035679)
225. da Silva F. P., Nizet V., Cell death during sepsis: integration of disintegration in the inflammatory response to overwhelming infection. Apoptosis 2009 14 4 509 521 2-s2.0-62449251424 10.1007/s10495-009-0320-3
226. Taylor F. B. Jr., Chang A., Esmon C. T., Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. The Journal of Clinical Investigation 1987 79 3 918 925 2-s2.0-0023122016 (Pubitemid 17050920)
227. Bernard G. R., Ely E. W., Wright T. J., Fraiz J., Stasek J. E. Jr., Russell J. A., Mayers I., Rosenfeld B. A., Morris P. E., Yan S. B., Helterbrand J. D., Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Critical Care Medicine 2001 29 11 2051 2059 2-s2.0-0035164538 (Pubitemid 33063531)
228. Bernard G. R., Vincent J., Laterre P., LaRosa S. P., Dhainaut J., Lopez-Rodriguez A., Steingrub J. S., Garber G. E., Helterbrand J. D., Ely E. W., Fisher C. J., Efficacy and safety of recombinant human activated protein C for severe sepsis. The New England Journal of Medicine 2001 344 10 699 709 2-s2.0-0035826096 10.1056/NEJM200103083441001 (Pubitemid 32204987)
229. Dellinger R. P., Levy M. M., Carlet J. M., Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Critical Care Medicine 2008 36 1 296 327
230. Ranieri V. M., Thompson B. T., Barie P. S., Drotrecogin alfa (activated) in adults with septic shock. The New England Journal of Medicine 2012 366 22 2055 2064